User:Mr. Ibrahem/Anifrolumab

Anifrolumab, sold under the brand name Saphnelo, is a medication used to treat systemic lupus erythematosus (SLE). Specifically it is used for moderate to severe disease that is not controlled by usual treatments. It is given by injection into a vein.

The most common side effects are upper respiratory infections and bronchitis. Other side effects may include shingles. Safety in pregnancy is unclear. It is a monoclonal antibody that binds to type I interferon receptor, blocking the activity of type I interferons.

Anifrolumab was approved for medical use in the United States in 2021 and Europe in 2022. In the United States it costs about 5,000 USD per dose as of 2022. It is not commercially available in the United Kingdom as of 2022.